FDA Clearance Tracker · P140015-S021
t:slim G4 Insulin Pump with Dexcom G4 Platinum CGM
Last checked: Nov 20, 2026Latest source record: Dec 21, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Dec 21, 2017
Approved
Time to decision
262 days
Received Apr 3, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P140015-S021
- Device name
- t:slim G4 Insulin Pump with Dexcom G4 Platinum CGM
- Applicant
- Tandem Diabetes Care, Inc.
- Applicant location
- San Diego, CA
- Received
- Apr 3, 2017
- Decided
- Dec 21, 2017
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P140015
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for a manufacturing site change of the t:Slim G4 Insulin Pump, which is used with the Dexcom G4 Platinum CGM, from their old facility at 11045 Roselle St, San Diego, California to their new facility at 10151 Barnes Canyon Rd, San Diego, California.
Source documents
Other decisions for Tandem Diabetes Care, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Control-IQ+ technology510(k)
K260429 · Decided Apr 24, 2026 · 73 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.